New Premier study suggest Preterax as a first-line antihypertensive.
D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000150:complications / Q000188:drug therapy; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D003971:Diastole / Q000187:drug effects; D004232:Diuretics / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000008:administration & dosage; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007190:Indapamide / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D020913:Perindopril / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D013599:Systole / Q000187:drug effects; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004232:Diuretics; D004338:Drug Combinations; C494243:indapamide, perindopril drug combination; D004656:Enalapril; D007190:Indapamide; D020913:Perindopril